Latest Regulatory Filings News

James Hardie Industries saw a 25% sales increase in FY26 driven by the AZEK acquisition but reported a 75% net income decline amid acquisition costs and margin pressures. The company expects synergy gains and adjusted EBITDA growth in FY27.

Lumos Diagnostics advances US commercial rollout of FebriDx with positive reimbursement data and expanded urgent care adoption ahead of the 2027/28 flu season.

Coda Minerals has launched critical drilling and environmental programmes at its Elizabeth Creek Copper-Silver Project, underpinning its Pre-Feasibility Study and potential resource expansion.

Neurizon Therapeutics has gained ethics approval to start a Phase 1 trial of its NUZ-001 oral liquid formulation, aiming to ease treatment for ALS patients with swallowing difficulties.

Anteris Technologies reported a $22.9 million net loss in Q1 2026 but bolstered its cash position to $283 million following a $320 million capital raise. The company is scaling manufacturing and clinical activities for its DurAVR transcatheter heart valve, with US patient enrolment now underway in the pivotal PARADIGM Trial.

Avecho Biotechnology has bolstered its cash reserves by $1.9 million through the exercise of listed options, positioning the company for a pivotal Phase III interim analysis readout for its insomnia treatment.

The Supreme Court of Western Australia has approved the acquisition schemes allowing Li-FT Power to take full ownership of Winsome Resources, with trading suspension on the ASX set for 12 May 2026.

BPH Global inks binding deal with Temasek Innovation Holdings to validate its seaweed-based male vitality product through targeted biological assays, advancing regulatory and commercial ambitions.

Aurizon reports volume growth across coal, bulk, and container freight for ten months to April, maintaining FY2026 EBITDA and dividend guidance amid a temporary $10 million fuel cost timing hit.

NeuRizer Ltd advanced its urea project with Reliance Industries payments and environmental submissions, despite ongoing ASX trading suspension and overdue financial reports.

Noxopharm’s SOF-16 active ingredient demonstrated potent anti-inflammatory activity in patient-derived samples of systemic lupus erythematosus and rheumatoid arthritis, advancing its Sofra™ platform beyond topical applications.

Recce Pharmaceuticals bolsters its clinical and commercial pipeline with a $5.3 million AUD R&D tax rebate, a second U.S. Army research agreement for its RECCE 327 Gel, and a key patent granted in Brazil, while progressing Phase 3 trials in Indonesia.